About Acromegaly

About Somatuline^® Depot

Simple, Patient-Friendly Delivery

Powerful, Long-Term Efficacy

Safety and Tolerability

Pharmacokinetic Profile

Dosing of Somatuline^® Depot

Who's Right for Somatuline^® Depot?

Reimbursement Assistance

Resources for Healthcare Professionals

Full Prescribing Information

to For Patients

Somatuline Depot referral form

Somatuline Depot coupon

Sign Up for Updates

to For Patients

About Somatuline Depot (lanreotide) Injection

For your patients with acromegaly, Somatuline Depot is a simply effective way to go

The first acromegaly treatment available in a 28-day prefilled syringe, Somatuline Depot is something for your patients.1,2

With Somatuline Depot, you can offer your patients the freedom of a simple, deep subcutaneous injection.1 Find out more about how Somatuline Depot is patient- and professional-friendly. And see how Somatuline Depot is injected in a short video.

See if your patients would benefit from the powerful, long-term efficacy of Somatuline Depot.1

Learn about the proven safety and tolerability of Somatuline Depot, including a low discontinuation rate and a demonstrated cardiovascular profile.1,2

Look into a pharmacokinetic profile that may deliver efficacy in 24 hours through its selective binding to key somatostatin receptors.1,10

Discover the flexibility and convenience of three different Somatuline Depot dosing strengths.1

Determine which of your patients are right for Somatuline Depot by reading about three distinct types of patients with acromegaly.

Read more within the Full Prescribing Information.

Learn about simple, patient-friendly delivery

Somatuline Depot is designed to help your patients manage acromegaly with the least amount of discomfort. Find out more about how Somatuline Depot is delivered.

How to inject Somatuline Depot

Somatuline Depot is injected in an easy, two-step injection process.1 Learn more about injecting Somatuline Depot.

Who should take Somatuline Depot

Somatuline Depot is indicated for the long-term treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation. It is also for patients who cannot tolerate surgery or radiation.1 Find out more about who should take Somatuline Depot.

IMPORTANT SAFETY INFORMATION

Somatuline^® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline^® Depot may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline^® Depot 60mg.

There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are no always predictive of human responses, Somatuline^® Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline^® Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline^® Depot may reduce the intestinal absorption of co-administered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.

Please see Full Prescribing Information for additional important information.

SOMATULINE^® DEPOT IS MARKETED BY TERCICA, INC. AND MANUFACTURED BY IPSEN PHARMA BIOTECH (SIGNES, FRANCE).

THIS WEB SITE IS INTENDED FOR US RESIDENTS ONLY. TERCICA, INC. ALL RIGHTS RESERVED.

© 2008 Tercica Legal Notices | Privacy Statement